New drug shows promise for Sjögren's syndrome in early trial
NCT ID NCT04078386
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a biologic drug called RC18 in 42 people with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. Participants received weekly injections of either RC18 (at 160 mg or 240 mg) or a placebo for 24 weeks. The goal was to see if RC18 could safely reduce disease activity, measured by a standard score (ESSDAI). The study is complete, and results may show whether RC18 can help control this chronic condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RC18 (a biologic drug that blocks a protein involved in immune system activity)
What this could lead to
If it works, this could lead to a new treatment option to control disease activity in people with primary Sjögren's syndrome.
What could go wrong
This is an early phase 2 trial with only 42 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Hospital
Beijing, China
-
Huzhou Third Municipal Hospital
Huzhou, Zhejiang, China
-
Peking Union Medical College Hospital
Beijing, China
-
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
-
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, China
-
The First Affiliated Hospital of USTC，Anhui Provincial Hospital
Hefei, Anhui, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, China
-
The First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
-
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
-
Tianjin Medical University General Hospital
Tianjin, China
-
West China School of Medicine，West China Hospital of Sichuan University
Chengdu, China